Toyama, Japan

Takako Yokozawa


Average Co-Inventor Count = 3.4

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 1994-2011

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Takako Yokozawa: Innovator in Diabetes and Hypertension Treatments

Introduction

Takako Yokozawa is a prominent inventor based in Toyama, Japan. She has made significant contributions to the fields of diabetes and hypertension treatment through her innovative research and patented compositions. With a total of 2 patents, her work focuses on developing safe and effective therapeutic solutions.

Latest Patents

Yokozawa's latest patents include a preventive, relieving, or therapeutic composition for diabetes mellitus and/or diabetic nephropathy. This composition aims to provide a treatment that minimizes side effects while ensuring high safety. It contains various dietary fibers, such as degraded galactomannan, indigestible dextrin, and inulin, among others. Additionally, she has developed an antihypertensive method that involves administering a pharmaceutical agent containing lithospermic acid B to hypertensive patients, showcasing her commitment to improving health outcomes.

Career Highlights

Throughout her career, Takako Yokozawa has worked with notable companies, including Minophagen Pharmaceutical Co., Ltd. and Taiyo Kagaku Co., Ltd. Her experience in these organizations has allowed her to advance her research and contribute to the development of innovative medical solutions.

Collaborations

Yokozawa has collaborated with esteemed colleagues, including Hikokichi Oura and Itsuo Nishioka. These partnerships have further enriched her research and expanded the impact of her inventions.

Conclusion

Takako Yokozawa's contributions to diabetes and hypertension treatments highlight her role as a leading inventor in the medical field. Her innovative patents and collaborations reflect her dedication to improving patient care and advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…